Recent trends in the management of antiphospholipid syndrome (Hughes syndrome)

Drugs of Today

Volumn 46, Issue 1, 2010, Pages 39-47

  Espinosa, Gerard ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT INHIBITOR; COUMARIN; CYTOKINE ANTIBODY; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHOLIPID ANTIBODY; RITUXIMAB; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; HEMOSTASIS; HEPARINIZATION; HUMAN; PATHOGENESIS; REVIEW; SPONTANEOUS ABORTION; THROMBOSIS; VEIN THROMBOSIS;

EID: 77951429490     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.1.1416982     Document Type: Review

References (51)

1. Miyakis, S., Lockshin, M.D., Atsumi, T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4(2): 295-306.
2. Urbanus, R.T., Derksen, R.H., de Groot P.G. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev 2008, 22(2): 93-105.
3. Salmon, J.E., de Groot, P.G. Pathogenic role of antiphospholipid antibodies. Lupus 2008, 17(5): 405-411
4. Ruiz-Irastorza, G., Khamashta, M.A. The treatment of antiphospholipid syndrome: A harmonic contrast. Best Pract Res Clin Rheumatol 2007, 21(6): 1079-1092 (Pubitemid 350194042)
5. Ruiz-Irastorza, G., Hunt, B.J., Khamashta, M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007, 57(8): 1487-1495 (Pubitemid 350308848)
6. Derksen, R.H., Khamashta, M.A., Branch, D.W. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004, 50(4): 1028-1039
7. 2-glycoprotein I only after a conformational change. Blood 2006, 107(5): 1916-1924
8. 2-glycoprotein I antibody complexes. J Biol Chem 2001, 276(5): 3060-3067 (Pubitemid 37411596)
9. Espinosa, G., Cervera, R., Font, J., Shoenfeld, Y. Antiphospholipid syndrome: Pathogenic mechanisms. Autoimmun Rev 2003, 2(2): 86-93.
10. 2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007, 56(5): 1638-47. (Pubitemid 46764093)
11. Dentali, F., Manfredi, E., Crowther, M., Ageno, W. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 2005, 3(9): 2121-2123 (Pubitemid 43086081)
12. Vargas, J., Sangle, S.R., Barrutia, O.A., D'Cruz, D.P., Khamashta, M.A. Efficacy and safety of long term low molecular weight heparin in antiphospholipid patients. 73rd Ann Sci Meet American Coll Rheumatol (October, 17-21) 2009, Abs 1284.
13. Girardi, G., Berman, J., Redecha, P. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003, 112(11): 1644-54. (Pubitemid 38063722)
14. Kearon, C., Kahn, S.R., Agnelli, G., Goldhaber, S., Raskob, G.E., Comerota, A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133(6 Suppl.): 454S-545S. (Pubitemid 351892969)
15. Girardi, G., Redecha, P., Salmon, J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10(11): 1222-1226 (Pubitemid 39540439)
16. Weitz, J.I., Hirsh, J., Samama, M.M. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133(6 Suppl.): 234S-56S. (Pubitemid 351892961)
17. 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000, 275(20): 15541-15548 (Pubitemid 30337288)
18. Shoenfeld, Y., Ziporen, L. Lessons from experimental APS models. Lupus 1998, 7 (Suppl. 2): S158-61.
19. Raschi, E., Testoni, C., Bosisio, D., Borghi, M.O., Koike, T., Mantovani, A., Meroni, P.L. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 101(9): 3495-3500 (Pubitemid 36857933)
20. Kornberg, A., Blank, M., Kaufman, S., Shoenfeld, Y. Induction of tissue factor-like activity in monocytes by anticardiolipin antibodies. J Immunol 1994, 153(3): 1328-1332 (Pubitemid 24228525)
21. Lopez-Pedrera, C., Buendia, P., Cuadrado, M.J. et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006, 54(1): 301-311 (Pubitemid 43122214)
22. 2- glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007, 56(8): 2687-2697 (Pubitemid 47237287)
23. Pennings, M.T., Derksen, R.H., van Lummel, M. et al. Platelet adhesion to dimeric β-glycoprotein I under conditions of flow is mediated by at least two receptors: Glycoprotein Ib? and apolipoprotein E receptor 2′. J Thromb Haemost 2007, 5(2): 369-377
24. Vega-Ostertag, M.E., Pierangeli, S.S. Mechanisms of aPL-mediated thrombosis: Effects of aPL on endothelium and platelets. Curr Rheumatol Rep 2007, 9(3): 190-197
25. Ridker, P.M., Danielson, E., Fonseca, F.A. et al. Rosuvostatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21): 2195-2207
26. Ferrara, D.E., Liu, X., Espinola, R.G., Meroni, P.L., Abukhalaf, I., Harris, E.N., Pierangeli, S.S. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvostatin in an in vivo animal model. Arthritis Rheum 2003, 48(11): 3272-3279 (Pubitemid 37409342)
27. Belizna, C., Lartigue, A., Favre, J. et al. Antiphospholipid antibodies induce vascular functional changes in mice: A mechanism of vascular lesions in antiphospholipid syndrome? Lupus 2008, 17(3): 185-194 (Pubitemid 351588940)
28. Cuadrado, M.J., Lopez-Pedrera, C., Aguirre, A. et al. (2007) Changes operated in protein pattern of monocytes from patients with antiphospholipid syndrome treated with statins. 71th Ann Sci Meet American Coll Rheumatol (November, 6-10) 2007, Abs 2057.
29. Ferrara, D.E., Swerlick, R., Casper, K., Meroni, P.L., Vega-Ostertag, M.E., Harris, E.N., Pierangeli, S.S. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004, 2(9): 1558-1563 (Pubitemid 40186171)
30. Vega-Ostertag, M., Harris, E.N., Pierangeli, S.S. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004, 50(9): 2911-2919 (Pubitemid 39209530)
31. Edwards, M.H., Pierangeli, S., Liu, X., Barker, J.H., Anderson, G., Harris, E.N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997, 96(12): 4380-4384 (Pubitemid 28007469)
32. Ruiz-Irastorza, G., Khamashta, M.A. Hydroxychloroquine: The cornerstone of lupus therapy. Lupus 2008, 17(4): 271-273
33. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., Khamashta, M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2009 69(1): 20-28
34. Meroni, P.L., Raschi, E., Testoni, C., Tincani, A., Balestrieri, G. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am 2001, 27(3): 587-602.
35. Cugno, M., Borghi, M.O., Lonati, L.M. et al. Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 2009 Aug 3. [Epub ahead of print]
36. Forastiero, R.R., Martinuzzo, M.E., de Larrañaga, G.F. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005, 14(2): 129-136
37. Amengual, O., Atsumi, T., Khamashta, M.A. Tissue factor in antiphospholipid syndrome: Shifting the focus from coagulation to endothelium. Rheumatology 2003, 42(9): 1029-1031 (Pubitemid 37220988)
38. Zhou, H., Wolberg, A.S., Roubey, R.A. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004, 104(8): 2353-2358 (Pubitemid 39331833)
39. Burcoglu-O'Ral, A., Erkan, D., Asherson, R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 2002, 29(9): 2006-2011 (Pubitemid 34988713)
40. Pierangeli, S.S., Vega-Ostertag, M., Harris, E.N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: A pathway to targeted therapies. Thromb Res 2004, 114(5-6): 467-476 (Pubitemid 39429425)
41. 2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106(7): 2340-2346 (Pubitemid 41510805)
42. Oku, K., Atsumi, T., Bohgaki, M. et al Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009, 68(6): 1030-1035
43. Redecha, P., Tilley, R., Tencati, M., Salmon, J.E., Kirchhofer, D., Mackman, N., Girardi, G. Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007, 110(7): 2423-2431 (Pubitemid 47523163)
44. Pierangeli, S.S., Girardi, G., Vega-Ostertag, M., Liu, X., Espinola, R.G., Salmon, J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52(7): 2120-2124 (Pubitemid 40994335)
45. Holers, V.M., Girardi, G., Mo, L. et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195(2): 211-220 (Pubitemid 34461265)
46. Ioannou, Y., Lambrianides, A., Cambridge, G., Leandro, M.J., Edwards, J.C., Isenberg, D.A. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2008, 67(3): 425-426 (Pubitemid 351281283)
47. Youinou, P., Renaudineau, Y. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res 2004, 114(5-6): 363-369 (Pubitemid 39422568)
48. Kahn, P., Ramanujam, M., Bethunaickan, R. et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008, 58(9): 2824-2834
49. Edwards, J.C., Cambridge, G., Leandro, M.J. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006, 20(5): 915-928 (Pubitemid 44382384)
50. Furst, D.E., Keystone, E.C., Kirkham, B. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008, 67(Suppl. 3): iii2-25.
51. Erre, G.L., Pardini, S., Faedda, R., Passiu, G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: A case report and a review of literature. Lupus 2008, 17(1): 50-55 (Pubitemid 351487020)